Biologics with a total of $67 bln in global sales will lose patent protection by 2020
Twelve biologics with total global sales of $67 bln will meet generics competition by 2020.
The list includes such blockbusters as
- Avastin (bevacizumab)
- Herceptin (trastuzumab)
- Humira (adalimumab)
- Synagis (palivizumab)
- Erbitux (cetuximab)
- Remicade (infliximab)
- Rituxan/MabThera (rituximab)
- Enbrel (etarnecept)
- Epogen/Eprex (epoetin alfa)
- Neupogen (filgrastim)
- Lantus (insulin glargine)
and others.